Triad Isotopes

Summary

Chief Restructuring Officer

Orlando, FL

Triad Isotopes is the nation’s second largest radiopharmaceutical company, operating a network of cyclotrons and nuclear pharmacies strategically located across the US. offering nuclear medicine products to image, diagnose, and treat diseases; and cyclotrons for PET imaging. It serves national group purchasing organizations, regional systems, and stand-alone clinics and hospitals.

Triad was experiencing margin declines due to market competitive pressures, price pressure from large, national customers, as well as rising costs from sole source suppliers in an environment of declining volumes.

Key Challenges

Supplier Cost Pressure

Customer Pricing Pressure

Competitive Market

Declining Volumes

Unfair Business Practices

Engagement Highlights

Evaluated the company’s cost structure, implementing strategies to reduce costs and effecting initiatives to make the company the most efficient operator in the market.
Leveraged business relationships and market knowledge to negotiate more favorable contracts with suppliers to minimize price increases and abate the impact of bundling.
Repositioned the company’s market standing to improve customer hit and retention rates, while minimizing margin erosion.
Facilitating the M&A process of acquiring the number three competitor in the market, enabling the company to increase national footprint, acquire favorable pricing from proprietary manufacturers, stabilize market pricing, and better compete for market share.

Triad Isotopes

Summary

Chief Restructuring Officer

Key Challenges

Engagement Highlights

Sign Up for Our Newsletter